This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
Clinical trials funded by Novo Nordisk found that up to 23% of people taking semaglutide fell into the non-responder category, meaning they lost less than 5% of their body weight over the study period
No formal claim of superiority can be derived from these secondary endpoints under the original statistical plan, especially from regulatory standpoints
In some of these earlier discussions, the cytologic and clinical features of the tumors were overtly malignant, yet the term carcinoid tumor was applied without further modification, emphasizing the nomenclature problem discussed above
but those who are in their mid-30s and 40s are more likely to see it develop